Capital

Capital follows evidence.

R3i deploys and connects capital selectively where frontier technology, structural scarcity and credible institutional pathways converge.

Our investment work is informed by the same discipline as our transaction work: establish what is owned, what is proven, what remains uncertain and what must be true for value to compound.

Allocator enquiry

01 · Investment lens

Four tests, applied before conviction

01

Structural scarcity

We look for assets that remain difficult to reproduce as software, models and information become increasingly abundant — proprietary science, intellectual property, validated data, industrial capability, regulated workflows, infrastructure or privileged access to market.

02

Evidence

Technical narrative is not enough. We look for proof proportionate to the underlying claim and the capital required to advance it.

03

Institutional pathway

The technology must ultimately become legible to customers, regulators, strategic partners and future capital.

04

Capital fit

The structure, duration and expectations of capital must match the actual development pathway.

02 · Areas of attention

One taxonomy, applied consistently

The same three domains govern transaction work and capital work. Sector boundaries matter less than whether the asset is scarce, defensible and capable of becoming institutionally executable.

01

Strategic technologies

AI · advanced compute · autonomy · defence

02

Critical systems

Energy · water · industrial infrastructure · critical materials

03

Human systems

Health · life sciences

03 · For allocators

Built for investors comfortable underwriting complexity, but not ambiguity

Institutional and strategic capital relationships are developed around specific opportunities, vehicles and mandates rather than generic access — including sovereign and pre-IPO secondaries in artificial intelligence, space, defence, critical infrastructure and biotechnology, where regulatory and ownership review shape who can participate.

Depending on structure, investors may engage with R3i around:

  • sovereign and pre-IPO secondaries in high-risk, regulator-adjacent sectors;
  • selected direct or co-investment opportunities;
  • transaction-specific vehicles;
  • defined managed strategies, where offered.

Vehicles are named, and their status stated, only in confidential offering documentation. Nothing on this page is an offer of securities, and no vehicle is represented as open for subscription.

Allocator enquiry

04 · Conflicts

Conflicts are disclosed by mandate

R3i may act as originator, adviser, investor or vehicle sponsor. The applicable role and any related-party interest are disclosed by mandate, before terms are agreed. Fee arrangements are disclosed in priority order, not layered silently, and Investment Committee members recuse themselves from decisions in which they hold a personal or related-party interest.

A risk-based AML/KYC policy applies across all entities and is a precondition of any commitment. R3i does not accept client transaction capital into its operating-company accounts.

Legal & regulatory architecture →

R3i.vc · Capital — informational only